Humanwell Healthcare (group) Co.,ltd. Class ASSE: 600079

(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Signing Supplemental Agreement (II) to the Conditional Share Subscription Agreement for the Private Placement of Shares with the Controlling Shareholder and Related Party Transaction

· Issued by Humanwell Healthcare (group) Co.,ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Stock code 600079 · · 3 pages · Chinese

Summary by 6ix

Humanwell Healthcare (Group) Co., Ltd. has announced the signing of a supplemental agreement related to a conditional share subscription agreement with its controlling shareholder, which involves a related party transaction. The agreement outlines adjustments to the share subscription terms, including the subscription amount and other key details. The transaction is classified as a related party transaction but does not constitute a major asset restructuring as defined by regulations. The company has stated that the transaction is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission, indicating potential uncertainties.

6ix wrote this summary in English from the company’s filing.

Written in English by 6ix from the Chinese-language filing.

l 人福医药集团股份公司（以下简称“公司”）拟向特定对象发行 A 股股票（以下简称“本次发行”），发行对象为控股股东招商生命科技（武汉）有限公司（以下简称“招商生科”），鉴于公司对本次发行方案进行了调整，公司与招商生科签署了《人福医药集团股份公司向特定对象发行股票之附条件生效的股份认购协议之补充协议（二）》（以下简称“《补充协议（二）》”）。 l 上述交易事项构成关联交易，不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 l 本次发行尚需经上海证券交易所（以下简称“上交所”）审核通过并经中国证券监督管理委员会（以下简称“中国证监会”）同意注册后方可实施，能否最终完成尚存在不确定性，敬请广大投资者注意投资风险。 l 截至本公告披露日，过去 12 个月内，公司及子公司未与招商生科发生关联交易。公司未与其他关联人进行与本次交易类别相关的交易。 一、关联交易概述 公司分别于 2026 年

Company analysis

Earlier from Humanwell Healthcare (group) Co.,ltd. Class A

All Humanwell Healthcare (group) Co.,ltd. Class A news releases